Piramal Group

Piramal, TPG on verge exit from Shriram General Insurance Holdings

Likely to sell combined stake of 30% in the company at an enterprise valuation of $2 billion, say sources

Piramal Capital aims to increase retail loan book to more than Rs 1 trn

Piramal Capital & Housing Finance expects to grow its retail loan book to more than Rs 1 lakh crore over the next three years from around Rs 25,000 crore now

Cosmea-Piramal consortium pulls out of Reliance Capital's bidding

With the exit of Cosmea-Piramal, there are now only three players left in the race -- Hinduja, Torrent, and Oaktree

CoC raises base price of Reliance Capital auction to Rs 6,500 crore

Auction to be held on two days, starting December 22

Piramal, Zurich Insurance may bid separately for Reliance General Insurance

Piramal, Zurich Insurance may bid separately for Reliance General Insurance

RCapital lenders meet ends in stalemate over key challenge mechanism issue

CoC decides that all bidders, while submitting their resolution plans, will agree in writing to participate in the Challenge Mechanism in whatever form it is implemented by the lenders later

MSCI sets aside Piramal Pharma's exclusion from global standard index

The company was listed separately on October 19, following its demerger from Piramal Enterprises

We won't make an acquisition just because we have to: Piramal Pharma chief

In a Q&A, Nandini Piramal, chairperson of the firm, says the company currently sees great scope in expanding and organically growing the OTC business, and wants to build more consumer focused brands

Piramal Pharma ends at Rs 192 on debut, valued at Rs 22,882 cr at close

Domestic brokerage Motilal Oswal has set a price target of Rs 210 for the stock

Piramal Pharma lists at Rs 202 on BSE; shares tumble 5% intra-day

In October 2021, the board of directors of Piramal Enterprises (PEL) had approved the demerger of the pharmaceuticals business, and simplification of the corporate structure

Piramal Pharma receives Sebi's nod to list shares on Indian bourses

Piramal Pharma on Thursday said it has received an approval from the Securities and Exchange Board of India (Sebi) to list shares on domestic stock exchanges. Piramal Pharma, consequent to the approval granted by the National Company Law Tribunal (NCLT), has been demerged from Piramal Enterprises Ltd (PEL) as a part of the simplification of the corporate structure. Piramal Pharma Ltd (PPL) has received a letter from Sebi...the company expects that its shares will be listed on the Indian equity stock exchanges -- BSE and NSE -- next week, it said in a statement. The demerger from PEL will firmly empower PPL to be future ready and enable it to independently pursue its growth strategies with sharper focus and identity, it added. In consideration of the demerger, shareholders of PEL have been allotted four shares of PPL for every one share in PEL, in addition to their existing holding in PEL, the company said. PPL includes Piramal Pharma Solutions (PPS), Piramal Critical Care (PCC) an

Led by HDFC twins, India sees record $124-billion M&A deals in H1FY23

Bankers said the second half of the ongoing financial year will be led by government divestments

Piramal, Zurich Insurance to bid jointly for Reliance General Insurance

Administrator pegs general insurance arm valuation at Rs 9,450 crore

Reliance Capital bidders seek more time from lenders to make final offers

Banking sources said Piramal group has sought 12 weeks' extension, while PE major Advent wants time till Jan-end 2023, citing delays in completing due diligence

Piramal Group charts growth path for financial services business

'We are on track to achieve retail loan disbursements of Rs 2,500 cr-3,500 cr in Q3FY23,' which is 5-7 times of pre-merger levels, says Piramal Group chairman Ajay Piramal

Piramal Enterprises Q1 net profit slips 9% to Rs 486 cr; revenue up 22%

Piramal Enterprises Ltd on Friday reported an 8.95 per cent decline in consolidated net profit to Rs 485.98 crore for the first quarter ended June 30, impacted by higher expenses. The company had posted a consolidated net profit of Rs 533.79 crore in the same period last fiscal, Piramal Enterprises Ltd (PEL) said in a regulatory filing. Its revenue from operations in the first quarter stood at Rs 3,548.37 crore compared to Rs 2,908.68 crore in the year-ago period, it added. Total expenses in the quarter were higher at Rs 3,252.09 crore against Rs 2,492.97 crore a year ago. PEL said its pharmaceuticals vertical clocked revenue of Rs 1,485.43 crore, up from Rs 1,362.02 crore in the year-ago quarter. The financial services segment registered a revenue of Rs 2,062.94 crore against Rs 1,546.66 crore in the first quarter of the last fiscal, the company added. "In financial services, we achieved significant growth in retail disbursements through our branches as well as by leveraging dig

Pharma companies with quality compliance to be stronger: Piramal

Pharmaceutical businesses that have a strong track record of quality compliance and can remain agile towards new regulatory requirements, will emerge stronger as the impact of the pandemic decreases, according to Piramal Enterprises Ltd Chairman Ajay G Piramal. Addressing shareholders in the company's annual report for 2021-22, Piramal said the company's pharma vertical is expected to have nearly 15 per cent CAGR revenue growth across businesses in the medium to long-term. "In the current circumstances, the pharmaceutical sector has emerged as an essential industry, with an ever-more critical role in today's evolving world," he wrote. Stating that the world's economy and infrastructure continue to be affected by significant supply chain disruptions and volatility in raw material costs, Piramal said safeguarding the supply chain is extremely critical and the company's teams have been pro-actively working towards diversifying vendor base and obtaining alternative suppliers to reduce .

Piramal Group not eligible to acquire Reliance Capital, says Irdai

Group has promoter stake in Pramerica Life Insurance

Piramal Group chairman awarded for services to UK-India trade relationship

Piramal Group Chairman Ajay Piramal has received the prestigious Commander of the Order of the British Empire (CBE) award, a release said on Tuesday. Piramal has received the award for services to the UK-India trade relationship as India Co-Chair of the UK-India CEO Forum. Piramal said: "I am humbled and honoured to receive this honorary award from Her Majesty The Queen." As co-chair of India-UK CEO forum since 2016, the endeavour has been to help strengthen the strong bilateral relations between the two countries through greater economic co-operation, he added. "I'm delighted that Her Majesty The Queen has, in her Jubilee Year, approved Ajay Piramal an honorary CBE in recognition of the leading role Ajay has played in the UK-India relationship," Alan Gemmell, Her Majesty's Trade Commissioner for South Asia and British Deputy High Commissioner for Western India, said. The Commander of the Order of the British Empire (CBE) is awarded for having a prominent role at national level.

Piramal Pharma ropes in Ajay Devgn for skin-care brand Tetmosol

Piramal Pharma on Monday said its consumer products division has roped in Bollywood actor Ajay Devgn for its flagship brand Tetmosol.